Nuvalent
resistance mutations induced rapid responses in resistant patients erase a with tumor | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
19 of 31
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
key subgroups phase resistance mutations subgroup with known resistance mutation induced rapid responses in resistant patients reduction in tumor burden in cancers with i a i a a a i a a reduction in allele complete clearance in patients with tumor shrinkage months weeks one patient with with ongoing pending confirmation activity intracranial in patients with measurable metastases of in response evaluable patients with history of metastases no progression observed in any of the treated patients source a induced responses in intracranial lesions weeks weeks intracranial response in year old female with fusion previously treated with chemotherapy and with progression and no known resistance mutations patient continues at months with ongoing response images courtesy of lin general hospital each unique color indicates data from the same patient across both figures due to new lesions and or progression of lesions prior treatments include best response on data as of for patients treated by central nervous system circulating tumor acid non small cell lung cancer objective response rate progressive disease partial response once daily stable disease tyrosine kinase inhibitor includes ongoing partial response pending confirmation central analysis by guardant includes patients with detectable at and at least one on treatment follow up assessment bar represents week result week results are pending one patient with an ongoing intracranial pending confirmation includes ongoing partial responses pending confirmation | Nuvalent
Investor Presentation
February 2024
key subgroups phase induced rapid responses in resistant patients reduction in tumor burden in cancers with resistance mutations subgroup with known resistance mutation with tumor shrinkage one patient with with ongoing pending confirmation activity intracranial in patients with measurable metastases of in response evaluable patients with history of metastases no progression observed in any of the treated patients source a reduction in allele complete clearance in patients i a i a a a i a a months weeks induced responses in intracranial lesions weeks weeks intracranial response in year old female with fusion previously treated with chemotherapy and with progression and no known resistance mutations patient continues at months with ongoing response images courtesy of lin general hospital each unique color indicates data from the same patient across both figures due to new lesions and or progression of lesions prior treatments include best response on data as of for patients treated by central nervous system circulating tumor acid non small cell lung cancer objective response rate progressive disease partial response once daily stable disease tyrosine kinase inhibitor includes ongoing partial response pending confirmation central analysis by guardant includes patients with detectable at and at least one on treatment follow up assessment bar represents week result week results are pending one patient with an ongoing intracranial pending confirmation includes ongoing partial responses pending confirmation | Nuvalent
Investor Presentation
January 2024
key subgroups a a i induced rapid responses in resistant patients reduction in tumor burden in cancers with resistance mutations subgroup with known resistance mutation with tumor shrinkage one patient with with ongoing pending confirmation activity intracranial in patients with measurable metastases of patients with history of metastases in response evaluable no progression observed in any of the treated patients source a reduction in allele complete clearance in patients i a i a a a i a a months weeks induced responses in intracranial lesions weeks intracranial response in year old female with fusion previously treated with chemotherapy and with progression and no known resistance mutations patient continues at months with ongoing response images courtesy of lin general hospital each unique color indicates data from the same patient across both figures due to new lesions and or progression of lesions prior treatments include best response on data as of for patients treated by central nervous system circulating tumor acid non small cell lung cancer objective response rate progressive disease partial response once daily stable disease tyrosine kinase inhibitor includes ongoing partial response pending confirmation central analysis by guardant includes patients with detectable at and at least one on treatment follow up assessment bar represents week result week results are pending one patient with an ongoing intracranial pending confirmation includes ongoing partial responses pending confirmation | Nuvalent
Investor Presentation
January 2024
key subgroups a a i induced rapid responses in resistant patients reduction in tumor burden in cancers with resistance mutations subgroup with known resistance mutation with tumor shrinkage one patient with with ongoing pending confirmation activity intracranial in patients with measurable metastases of patients with history of metastases in response evaluable no progression observed in any of the treated patients source a reduction in allele complete clearance in patients i a i a a a i a a months weeks induced responses in intracranial lesions weeks intracranial response in year old female with fusion previously treated with chemotherapy and with progression and no known resistance mutations patient continues at months with ongoing response images courtesy of lin general hospital each unique color indicates data from the same patient across both figures due to new lesions and or progression of lesions prior treatments include best response on data as of for patients treated by central nervous system circulating tumor acid non small cell lung cancer objective response rate progressive disease partial response once daily stable disease tyrosine kinase inhibitor includes ongoing partial response pending confirmation central analysis by guardant includes patients with detectable at and at least one on treatment follow up assessment bar represents week result week results are pending one patient with an ongoing intracranial pending confirmation includes ongoing partial responses pending confirmation | Nuvalent
Related slides by other companies
BioNTech
Results
March 2022
phase first in human study of | BioNTech
BioAtla
Investor Presentation
January 2024
phase cab demographics tumor types | BioAtla
Recursion Pharmaceuticals
Investor Day
January 2023
clinical well understood clinical safety with a drug like profile further confidence prior studies suggestive of potential therapeutic benefit | Recursion Pharmaceuticals
P3 Health Partners
Investor Conference
January 2022
proven outcomes and physician led we are able to drive enhanced outcomes via our patient centric physician led care model physician retention patient satisfaction annual revenue growth reduction in hospital admissions visits reduction in medical costs costs retention satisfaction admissions visits growth | P3 Health Partners
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io